CatalystMarker
← board

CABA

Cabaletta Biodistress 8/10 · high distress / dilution risk
$2.71-2%today-35% from 52w high
cabalettabio.com156 employeesFounded 2017Philadelphia, PABiotechnology
Neurology 1
Lead: myositis
Revenue
pre-revenue
Liquidity
$117M
Runway
0.8 yrs
Shares 1y
+78%

Price & events

-8.0% over 6M
$2.33$3.24$4.15Jan 26Apr 26Jul 2629.9Mdilution: 424B5 offering (2026-05-04)financing: 8-K material_agreement (2026-05-04)catalyst: PHASE1,PHASE2 rese-cel (2026-06-30) — click to opencatalyst: rese-cel (2026-06-30) — click to opencatalyst: PHASE1,PHASE2 rese-cel (2026-06-30) — click to opencatalyst: PHASE1,PHASE2 rese-cel (2026-06-30) — click to opencatalyst: PHASE1,PHASE2 rese-cel (2026-06-30) — click to opencatalyst: PHASE1,PHASE2 rese-cel (2026-06-30) — click to opencatalyst: PHASE1,PHASE2 rese-cel (2026-06-30) — click to opencatalyst: PHASE1,PHASE2 rese-cel (2026-05-14) — click to opencatalyst: PHASE1,PHASE2 rese-cel (2026-05-14) — click to openrating: Wells Fargo: Equal-Weight (2026-05-15)rating: Cantor Fitzgerald: Overweight (2026-05-04)rating: Morgan Stanley: Overweight (2026-03-24)rating: Guggenheim: Buy (2026-03-24)
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
+1.3%
1W
-10.4%
1M
-11.3%
3M
-14.9%
6M
+69.1%
1Y
-61.8%
2Y
-66.9%
5Y
-79.0%
All

Overview

Market Cap
$441.06M
Volume
203.81K
52 Week Range
$1.33 – $4.15
Total Shares
163.05M
Float Shares
142.90M
Short %
23.12%
% Held by Insiders
1.00%
% Held by Institutions
64.32%
RVOL
0.04x
Beta
3.26

Pipeline stages · 3 programs

CABA-201
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2028-07
DSG3-CAART, CABA-201
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2029-01
MuSK-CAART
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved

Pipeline · 6 trials · 5 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2028-07
Estimated 50%
readout ~2028-09-14
Phase 2/3CABA-201 following preconditioning with fludarabine and cyclophosphamideIdiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis—recruiting
2029-01
Estimated 50%
readout ~2029-02-15
Phase 1/2DSG3-CAART, CABA-201Pemphigus Vulgaris—recruiting
2029-07
Estimated 50%
readout ~2029-08-15
Phase 1/2CABA-201Systemic Sclerosis, Scleroderma—recruiting
2029-09
Estimated 50%
readout ~2029-10-16
Phase 1/2CABA-201Generalized Myasthenia Gravis (gMG)—active not recruiting
2029-12
Estimated 50%
readout ~2030-01-15
Phase 1/2CABA-201Systemic Lupus Erythematosus, Lupus Nephritis—recruiting
Show all 6 trials · 1 more ▾
ReadoutPhaseDrugIndicationEnrollStatus
2025-07-24
Phase 1MuSK-CAARTMuSK Myasthenia Gravis7completed

Catalyst news & presentations · 15

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 163,054,796 · 1 offerings/1y · 0 PIPEs
  • 2026-05-048-Kmaterial_agreement
  • 2026-05-04424B5offering
  • 2025-08-15EFFECTshelf_effective
  • 2025-08-07S-3shelf_registration
  • 2025-06-128-Kmaterial_agreement
  • 2025-06-12424B5offering
  • 2025-06-11424B5offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $13 (+394% upside) · 8 analysts
  • 2026-05-15Wells FargoEqual-Weight
  • 2026-05-04Cantor FitzgeraldOverweight
  • 2026-03-24Morgan StanleyOverweight
  • 2026-03-24GuggenheimBuy
  • 2025-10-31Cantor FitzgeraldOverweight
  • 2025-10-10HC Wainwright & Co.Buy

Competitors — myositis

  • PFEPFIZER INC$142.2B · D3
  • ARGXARGENX SE$54.3B · D0
  • ROIVRoivant Sciences Ltd.$25.1B · D0
  • GLPGFLakefront Biotherapeutics NV$1.9B · D0
  • RNACCartesian Therapeutics, Inc.$233M · D3
  • ARTVArtiva Biotherapeutics, Inc.$231M · D2
  • DTILPRECISION BIOSCIENCES INC$185M · D6
  • AZNASTRAZENECA PLC— · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.